Background: Mortality rates among adults with candidemia vary widely in different geographical settings. Studies directly comparing epidemiology and clinical practices between countries are scarce and could bring insights into improving clinical outcomes.
Methods: Retrospective cohort including adults with candidemia diagnosed in five tertiary hospitals from Brazil and Spain between 2010-2018. Adequate therapeutic management included appropriate antifungal therapy and central-venous-catheter (CVC) removal within 48 h of fungemia. Primary endpoints were mortality rates at 14 and 30 days. Secondary endpoints were prognostic factors associated with 30-day mortality.
Findings: Overall, 720 patients were included, being 323 from Spain. Spanish patients received echinocandins more often (52·5% vs. 39·3%, = 0.001), initiated antifungals earlier [2 (0-7) vs. 2 days (0-16), <0.001], and had faster CVC-removal [1 (0-42) vs. 2 days (0-38), = 0.012]. Mortality was higher among Brazilians at 14 days (35·8% vs. 20·1%, <0.001), and at 30 days (51·9% vs. 31·6%, < 0.001). Factors associated with mortality included: age [OR 1·02, 95%CI (1·008-1·032), = 0·001], neutropenia [OR 3·24, 95%CI (1·594-6·585), = 0·001], chronic pulmonary disease [OR 2·26, 95%CI (1·495-3·436), < 0·001], corticosteroids [OR 1·45, 95%CI (1·018-2·079), = 0·039], Pitt-Score>1 [OR 2·56, 95%CI (1·776-3·690), < 0·001], and inadequate therapeutic management [OR 2·84, 95%CI (1·685-4·800), < 0·001]. Being from Spain [OR 0·51, 95%CI (0·359-0·726), < 0·001] and [OR 0·36, 95%CI (0·233-0·568), < 0·001] were protective.
Interpretation: Higher mortality rates were observed in Brazil. Factors associated with 30-day mortality included mainly epidemiological characteristics and inadequate therapeutic management. Thus, effective and prompt antifungals combined with CVC-removal still need to be emphasized in order to improve the prognosis of adults with candidemia.
Funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2017/02203-7); CAPES Foundation (PDSE 88881.187981/2018-01).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904028 | PMC |
| http://dx.doi.org/10.1016/j.lana.2021.100117 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma Osteoprotegerin and Cognitive Impairment after Ischemic Stroke.
Curr Neurovasc Res
January 2025
Department of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, Jiangsu Province, China.
Background: Plasma osteoprotegerin (OPG) has been linked to poor prognosis following stroke, but its impact on post-stroke cognitive impairment (PSCI) is unknown. The purpose of our work was to analyze the relationship of OPG with PSCI.
Methods: Our study included 613 ischemic stroke subjects with plasma OPG levels.
Late Endovascular Treatment for Ischemic Stroke with Moderate to Large Infarct Volume is Associated with a Better Clinical Prognosis.
Curr Neurovasc Res
January 2025
Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Objective: The concept of "time is brain" is crucial for the reperfusion therapy of ischemic stroke. However, the Infarct Growth Rate (IGR) varies among individuals, which is regarded as a more powerful factor than the time when determining infarct volume and its association with clinical outcomes. For stroke patients with a similar infarct volume, a longer time from stroke Onset to Imaging (OTI) correlates with a lower IGR, which may indicate a better prognosis.
View Article and Find Full Text PDFSMARCB1/INI-1-Deficient sinonasal carcinoma demonstrates a poor prognosis but favorable clinical outcomes after PD-1/PD-L1 inhibitor therapy: A case series.
Sci Prog
January 2025
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Despite advances in multimodal cancer therapy, such as combining radical surgery with high-intensity chemoradiotherapy, for SMARCB1/INI-1-deficient sinonasal carcinoma (SDSC), the prognosis of patients remains poor. Immunotherapy is gaining increasing popularity as a novel treatment strategy for patients with SMARCB1/INI-1-deficient tumors. Herein, we report on the management of three patients with SDSC who received PD-1/PD-L1 inhibitor therapy as a part of multimodal therapy based on surgery and chemoradiotherapy.
View Article and Find Full Text PDFDouble-blind randomised trial of saline solution for gargling and nasal rinsing in SARS-CoV-2 infection.
J Glob Health
December 2024
Department of Anesthesiology, Critical Care and Pain Medicine, UTHealth, Houston, Texas, USA.
Background: Previous studies have shown that hypertonic saline nasal irrigation and gargling reduced the duration of symptoms in upper respiratory infections caused by coronavirus. This study aims to investigate the effects of two saline regimens on symptoms associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Methods: Between 2020 and 2022, individuals aged 18-65 years who tested positive for SARS-CoV-2 infection via polymerase chain reaction (PCR) were randomly assigned to either low- or high-saline regimens for 14 days.
Epstein-Barr Virus-Induced Hemophagocytic Lymphohistiocytosis: A Case Report of a Rare and Life-Threatening Syndrome.
Cureus
December 2024
Internal Medicine Department, Hamad Medical Corporation, Doha, QAT.
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening syndrome of excessive immune activation, leading to severe inflammation and organ damage. While more common in infants, HLH can occur at any age and is often triggered by infections such as Epstein-Barr virus (EBV). In this case, a 38-year-old man presented with a three-week history of fevers, night sweats, poor appetite, and severe anemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!